Schiodt M, Greenspan D, Dodd C, Chernoff D, Wara D, Leggott P, Hollander H, Greenspan J; International Conference on AIDS.
Int Conf AIDS. 1989 Jun 4-9; 5: 473 (abstract no. Th.B.P.347).
Oral AIDS Ctr, UCSF, San Francisco, CA, USA
OBJECTIVE: To describe the natural history of HIV-associated salivary gland disease (HIV-SGD), i.e., presence of salivary gland enlargement and/or xerostomia in HIV infection. METHODS: In 12 patients with HIV-SGD (1 child, 11 adults) followed for a median of 13 months we assessed symptoms, stage of HIV disease, resting whole salivary (RWS) flow rate (FR), stimulated parotid (SP) FR, and immune status (T4, T4/T8). The salivary FRs of the 9 with parotid gland enlargement (PGE) were compared with those of a control group of HIV infected adults without HIV-SGD but with a similar degree of immune deficiency. RESULTS: The symptoms of dry mouth and the parotid gland enlargement (PGE) were generally unchanged without treatment. PGE disappeared in 3 patients taking various medications (steroids, zidovudine). Acyclovir did not change the PGE in 2 patients. Patients with PGE had significantly lower salivary flow than the control group (P less than 0.01). TABULAR DATA, SEE ABSTRACT VOLUME. CONCLUSION: HIV-SGD is associated with low T4 counts and a high risk of development of AIDS. Patients with PGE have reduced parotid flows compared to HIV+ with similar immune deficiency. Unexpectedly, the salivary flow did not decrease with time in spite of further impaired immune status. This effect may partly be due to the given medications. The pathogenesis of this Sjogren's syndrome-like disease is unknown.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Adult
- Anti-HIV Agents
- Child
- Control Groups
- HIV
- HIV Infections
- HIV Seronegativity
- HIV Seropositivity
- Humans
- Parotid Diseases
- Parotid Gland
- Salivary Gland Diseases
- Xerostomia
- Zidovudine
- immunology
Other ID:
UI: 102178357
From Meeting Abstracts